Executive Summary:

Barricade Therapeutics, Corp.

Based in Dallas-Fort Worth, TX

Management Team: Extensive drug development and company-buliding experience . Over 70 years combined experience in the pharmaceutical industry. Led multiple first-in-human programs in U.S., Canada, and Europe.

- **Neil Thapar, PharmD, RPh**
  Chief Executive Officer & CSO
- **Melissa Krauth, MBA**
  Chief Business Officer
- **John Walling, PhD**
  Chief Operating Officer

Scientific Advisors:

- **Jef De Brabander, PhD**
  Synthetic Chemist, The Univ. of Texas Southwestern Medical Center (UTSW)
- **Deepak Nijhawan, MD, PhD**
  Clinical Oncologist, UTSW
- **Jerry Shay, PhD**
  Cell Biologist, UTSW
- **Sunil Sharma, MD, FACP., MBA**
  Clinical Oncologist, Deputy Director Tgen Clinical Sciences

Board of Directors: Experienced entrepreneurs responsible for multi-billion $ exits.

- **Al Guillem, PhD**
- **Darlene Boudreaux, CPA**
- **Neil Thapar**

Background:

- Advancing a first-in-class drug candidate, TASIN, targeting a gene mutation in >80% of colorectal cancer (CRC) patients
- Developing second TASIN as a disease-modifying therapy for Multiple Sclerosis
- Strong IP position with two issued patents
- Exclusive worldwide license with UTSW

Funding & Use of Proceeds:

- 2019: Closed $1.5MM Convertible Note
- 2020: Awarded CPRIT $3MM Product Development Seed for CRC Program
- Seeking $3MM Series A1 Preferred Round to advance programs to clinical development

Contact: Melissa Krauth, CBO
E-mail: mkrauth@barricadetherapeutics.com

BARRICADE THERAPEUTICS

Colorectal Cancer Program:

We are developing a potential blockbuster pill to treat and prevent colorectal cancer (CRC). CRC is one of the most common cancers, affecting 1.8 million people per year. Despite the best therapies available today, fewer than one in 12 patients with advanced CRC survives for five years, and almost 900,000 people die from CRC annually. With the need for better treatment options for these patients, the worldwide market opportunity is ~$10 Billion.

Our drugs, TASINs, specifically kill cancer cells containing the mutated or truncated APC gene without causing toxicity to normal cells. They take advantage of a fundamental vulnerability in these cells, which relates to the way they handle cholesterol. TASINs selectively inhibit a protein called EBP (emopamil binding protein), which leads to a reduction in cholesterol within the cell. Normal cells are unharmed by this block; however, cancer cells with our target mutation can't recover and die. The diagram below illustrates this process, which is a form of "synthetic lethality."

TASINs Cytotoxicity Overview:

TASIN disrupts intracellular cholesterol, which is critical for mutant-APC cancer cell survival



Barricade has studied TASIN drugs in many animal studies and found them effective against colon cancer and a precancerous condition called FAP. Additionally, TASINs are absorbed well when dosed orally and stay in the body for an appropriate period of time. The next step is to move the best TASIN into the final FDA-mandated studies to begin human trials. We expect to start human studies in 2021 in CRC patients with truncated APC, and to achieve human proof of concept within a year.

Neurology/Multiple Sclerosis (MS) Program:

The key biological process in MS and other neurological diseases is the destruction of a protein called myelin that insulates nerve cells. Inhibition of EBP, the molecular target of TASINs, in nerve cells (oligodendrocytes) has been demonstrated *in vitro* and in Gold Standard animal models to promote synthesis of myelin. This has the potential to stop or reverse the course of MS and is an area of intense interest by large pharmaceutical companies. Barricade has a number of highly potent EBP inhibitors that cross the blood-brain barrier and would be appropriate candidates for this high-value indication. While others are actively looking for compounds with these properties, Barricade appears to have a several-year head start in this area. Our current development plan is to select the best TASIN for MS during 2021, which would allow us to achieve human proof of concept in 2022.

Barricade has two issued patents that provide strong barriers to direct competition and market entry. IP has been diligenced multiple times by top-tier law firms. Our team has successfully developed multiple other drugs and advanced them to human clinical drug trials; as well as, having a long history of working together. We are targeting an exit through license of one or both programs, or by acquisition, upon achievement of human proof of concept. Recent comparables suggest exit values of $1B+ with positive clinical data in either indication.